Results 51 to 60 of about 98,415 (200)

Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis [PDF]

Journal of Biological Chemistry, 2003
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained ...
Li, Yazhou, Hansotia, Tanya, Yusta, Bernardo, Ris, Frédéric, Halban, Philippe A., Drucker, D. J.   +5 more
openaire   +3 more sources

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

Сахарный диабет, 2020
Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova   +2 more
doaj   +1 more source

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Glucagon-like peptide-1 receptor agonist versus basal insulin in type-2 diabetic patients: An efficacy and safety analysis [PDF]

, 2020
Purpose: To compare the effectiveness of glucagon-like peptide 1 receptor agonist with that of basal insulin in type 2 diabetes patients. Methods: Type-2 diabetes patients who were insensitive to metformin were treated with glucagon-like peptide 1 ...
Chen, Xiaxia, Feng, Min, Lin, Kaiping, Lin, Ting, Lv, Qi, Yang, Xiaoling   +5 more
core   +2 more sources

Glucagon‐like peptide‐1 receptor expression in the human eye [PDF]

Diabetes, Obesity and Metabolism, 2018
Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs placebo.
Josephine B. Hebsgaard, Charles Pyke, Emre Yildirim, Lotte B. Knudsen, Steffen Heegaard, Peter H. Kvist   +5 more
openaire   +4 more sources

Clinical pharmacology of glucagon-like peptide-1 receptor agonists

Hormones, 2018
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are an important asset in the armamentarium for the treatment of type 2 diabetes mellitus (type 2 DM). Incretin failure is a critical etiopathogenetic feature of type 2 DM, which, if reversed, results in improved glycaemic control.
Sfairopoulos, D., Liatis, S., Tigas, S., Liberopoulos, E.   +3 more
openaire   +3 more sources

Integrating the inputs that shape pancreatic islet hormone release. [PDF]

, 2019
The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core  

Differential effects of glucagon-like peptide-1 receptor agonists on heart rate [PDF]

, 2017
While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to increase heart rate (HR), it is insufficiently recognized that the extent varies greatly between the various agonists and is affected by the assessment methods employed.
A Asmar, A Asmar, A Ceriello, A Gill, A Jorsal, A Jorsal, A Plamboeck, AA Voors, AG Bertoni, Anne Lehmann, B Darpo, B Darpo, B Mendis, BM Scirica, C Perret-Guillaume, C Pyke, Christine Roy-Duval, David Owens, Denis Raccah, DJ Drucker, Francesca Lawson, GS Hillis, GS Hillis, H Linnebjerg, J Can van, J Skov, J Tillner, JA Lovshin, JJ Meier, JJ Meier, JR Ussher, K Swedberg, KB Margulies, KB Margulies, KC Ferdinand, KJ Griffioen, L Blonde, L Ryden, Lawrence Blonde, LE Robinson, LG Trahair, M Kim, M Komajda, M Lorenz, MA Nauck, MA Pfeffer, Martin Lorenz, MT Cooney, P Kumarathurai, P Sager, R Simo, Riccardo Perfetti, RR Holman, SE Inzucchi, SP Marso, T Vilsboll, X Zhou, Y Nakatani   +57 more
core   +1 more source

What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]

, 2019
Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra, Awad, Mohamed E., Eisa, Nada H., Elmansi, Ahmed M., Fulzele, Sadanand, Hamrick, Mark W., Herberg, Samuel, Hill, William D., Hussein, Khaled A., Isales, Carlos M., Kondrikov, Dmitry, McGee-Lawrence, Meghan E., Periyasamy-Thandavan, Sudharsan, Volkman, Brian F.   +13 more
core   +1 more source

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies [PDF]

, 2013
BACKGROUND: Lixisenatide is a glucagon-like peptide-1 analog which stimulates insulin secretion and inhibits glucagon secretion and gastric emptying.
BP Bullock, Daniel Crowther, Dominik Linz, DP Sonne, GG Sokos, Hartmut Ruetten, J Sivertsen, Jochen Huber, JR Ussher, JS Hochman, K Ban, K Ban, KD Schluter, L Timmers, LA Nikolaidis, M Korner, MG Vila Petroff, MH Noyan-Ashraf, MW Pfaffl, N Sarwar, Paulus Wohlfart, PT Campbell, Q Liu, RE Ratner, Sibylle Hess, T Nystrom, T Okerson, T Vilsboll, T Vilsboll, Thomas Hübschle, U Werner, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Ulrich Werner, Wolfgang Linz, Y Wei, Z Li   +35 more
core   +3 more sources